本公司接獲美國西南腫瘤集團通知，關於其主導OBI-3424之 T細胞急性淋巴性白血病（T-ALL）及T細胞淋巴母細胞淋巴瘤 (T-LBL)二期臨床試驗第一階段初步分析結果

首頁Announcements最新消息重大公告The Company received notice from SWOG regarding the analysis results of Phase II Stage 1 clinical trial of OBI-3424 in T-ALL and T-LBL